MAP1LC3B and breast cancer: Indeed, the effects of Raf-1 inhibitor, SOR, and Raf-1 knockdown on matching lipidated LC3B further confirm the ability of the Raf/MEK/ERK pathway to alter autophagic activity in breast cancer cells.